Rani Therapeutics Holdings Inc Cl A (RANI) Stock Price, Quote & News

Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes...

Industry: Biotechnology

Sector: Healthcare

Phone: 408 457 3700

Website: www.ranitherapeutics.com

Address:

2051 Ringwood Avenue, San Jose, United States

Mandalo Aug. 4 at 3:19 PM

$RANI $ACLX WELCOME ON BOARD MICHELLE GILSON ! 😇🤑👍 Michelle Gilson’s track record as a financial leader in biotech is nothing short of exceptional. During her tenure at Arcellx$ACLX, her strategic vision and capital management helped guide the company through remarkable growth, driving its value from around the $20 mark all the way to a blockbuster takeover valued at over $115 per share. Her appointment to the Board of Directors at Rani Therapeutics brings that exact high-caliber strategic expertise and proven Wall Street insight to the team. As Rani continues to advance its groundbreaking oral biologic delivery platform, having a powerhouse director like Michelle on board positions the company exceptionally well for its next phase of growth and shareholder value creation. 😇🤑👍

2 · Reply

kubota2323 Aug. 4 at 2:43 PM

$RANI adding more.

1 · Reply

Hakapeszi Aug. 4 at 12:14 PM

$RANI New experienced board member https://ir.ranitherapeutics.com/news-releases/news-release-details/rani-therapeutics-appoints-michelle-gilson-board-directors

2 · Reply

BinaryLogic Aug. 2 at 11:44 PM

$RANI [Again] It is important to highlight that the Rani-Pill offers a possible pill solution to ALL biologics globally over injection. That equates to a Total Addressable Market of nearly $56BILS, while the Company is presently valued at $105MILS. The Company is proceeding with its own product pipeline (separate and concurrent) across GLP1/2 (RT-114), $100BILS, Type-II Diabetes $10-20BILS, Osteoporosis RT-102 , Psoriasis $20BILS and others. The PT here near/intermediate term is approximately $3-8; however, the broad application of RaniPill across multiple biologics (as the partnerships with Chugai and PegBio suggest) could theoretically take the PT here long-term over $15-25 (IMO). It is presently trading at/around $0.70.

1 · Reply

wavw Jul. 31 at 1:53 PM

$RANI volume is decreasing day by day. MM may force retailers to sell by keeping price lower. In case if no one sells then MM may find hard to cover short positions.

1 · Reply

Jack696 Jul. 30 at 6:01 PM

$RANI everything green except this

2 · Reply

Mandalo Jul. 30 at 6:37 AM

Rani Therapeutics ($RANI) is hyper-focused on near-term clinical data readouts and non-dilutive Big Pharma partnerships to fund its pipeline. Key short-term catalysts and strategy: Clinical Milestones: Delivering key Phase 1/2 data readouts for high-value targets like RT-111 (psoriasis/psoriatic arthritis) and RT-114 (oral GLP-1/GLP-2 co-agonist for obesity). Big Pharma Collaboration: Leveraging the RaniPill platform to secure upfront cash, milestone payments, and co-development deals with major pharma players. Capital Efficiency: Managing cash burn carefully to extend runway and build enterprise value without relying solely on equity dilution. Data wins + big licensing deals = path to commercial validation and self-sustainability. 🚀💊 $RANI 😇🤑👍

0 · Reply

Hakapeszi Jul. 30 at 6:20 AM

$RANI In addition to the investment opportunity, we should not forget the importance of Ranipill: it can improve the lives of (hundreds of) millions of patients. It is true that it is not a life-saving invention, but it can eliminate many inconveniences. Just look around among your acquaintances, you will surely find those who have to regularly inject themselves with biologicals. Ask them if they were happy if there was a pill that would achieve the same effect without pain. In addition, there are no skin changes or irritation, which are very common with regular injections. This is what Rani promises. If they succeed, it will be groundbreaking.

2 · Reply

Mandalo Jul. 30 at 5:48 AM

$RANI has the multi-billion-dollar potential to mirror Halozyme's ($HALO) legendary platform success by mastering oral delivery. While $HALO revolutionized drug delivery by converting IV infusions into subcutaneous injections,$RANI takes the ultimate leap: turning injectable biologics into simple oral pills via the RaniPill®. Massive Market Opportunity: Unlocking oral delivery for immunology, osteoporosis, and GLP-1s disrupts huge global markets. Clinical De-risking: High bioavailability demonstrated across trials proves the mechanical micro-injector technology works in humans. Big-Pharma Catalyst: Future co-development licensing deals can transition $RANI from a micro-cap into a high-margin platform powerhouse. $RANI remains one of the most asymmetric, high-reward plays in biotech! 🚀 😇🤑👍

3 · Reply

Mandalo Jul. 30 at 5:18 AM

🔥 $RANI trading under $1.X is an absolute steal given the recent catalysts! 💎🙌 Phase 1a Win: RT-114 oral obesity pill showed >150% bioavailability vs. subcutaneous injections. Game-changer for oral GLP-1s! Partnership Momentum: PegBio collaboration expanding the obesity pipeline. Analyst Price Targets: Consensus sitting at $7.50–$8.75 (up to $11.00 high)—that’s massive upside from sub-$0.90 levels. Institutional Setup: New CFO hired & Q2 earnings around the corner. Wall Street is asleep at the wheel on oral bio-therapeutics. Accumulating before the big re-rate! 📈🐂 #Biotech #Bullish

2 · Reply

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-07-15T12:40:48.000Z - 20 days ago

Rani Therapeutics reports initial data from RT-114 study

Jul 15, 2026, 8:00 AM EDT - 20 days ago

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

2026-07-09T20:15:21.000Z - 25 days ago

Rani Therapeutics announces research, development collaboration with PegBio

Jul 9, 2026, 4:05 PM EDT - 25 days ago

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

2026-06-29T12:20:41.000Z - 5 weeks ago

Rani Therapeutics appoints Nicholas Maestas as CFO

TPST

Jun 29, 2026, 8:00 AM EDT - 5 weeks ago

Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer

May 28, 2026, 11:00 AM EDT - 2 months ago

Rani Therapeutics Holdings Transcript: AGM 2026

May 26, 2026, 8:00 AM EDT - 2 months ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules

May 15, 2026, 4:05 PM EDT - 2 months ago

Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition

May 15, 2026, 7:00 AM EDT - 2 months ago

Rani Therapeutics Holdings Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

Rani Therapeutics Holdings Earnings release: Q1 2026

May 12, 2026, 4:05 PM EDT - 2 months ago

Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference

Apr 16, 2026, 8:00 AM EDT - 3 months ago

Rani Therapeutics Holdings Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 3 months ago

Rani Therapeutics Holdings Proxy statement: Proxy filing

Apr 9, 2026, 7:00 AM EDT - 4 months ago

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

2026-04-01T11:31:50.000Z - 4 months ago

Rani Therapeutics price target lowered to $5 from $9 at Canaccord

Mar 26, 2026, 4:30 PM EDT - 4 months ago

Rani Therapeutics Holdings Earnings Call Transcript: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 4 months ago

Rani Therapeutics Holdings Annual report: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 4 months ago

Rani Therapeutics Holdings Earnings release: Q4 2025

Mar 26, 2026, 4:05 PM EDT - 4 months ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Mar 25, 2026, 4:53 PM EDT - 4 months ago

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Mar 19, 2026, 4:05 PM EDT - 4 months ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

2026-01-28T12:15:42.000Z - 6 months ago

Rani Therapeutics promotes Javadi to Chief Technical Officer

Jan 28, 2026, 7:00 AM EST - 6 months ago

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

2026-01-08T12:10:14.000Z - 7 months ago

Rani Therapeutics initiates Phase 1 study of RT-114 RaniPill

Jan 8, 2026, 7:00 AM EST - 7 months ago

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Nov 24, 2025, 4:05 PM EST - 9 months ago

Rani Therapeutics to Participate in the Evercore Healthcare Conference

2025-11-07T22:15:16.000Z - 9 months ago

Rani Therapeutics files to sell 42.63M shares of Class A common stock for holder

Nov 7, 2025, 7:00 AM EST - 9 months ago

Rani Therapeutics Holdings Registration statement: Registration Filing

Nov 6, 2025, 4:30 PM EST - 9 months ago

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

Nov 6, 2025, 7:00 AM EST - 9 months ago

Rani Therapeutics Holdings Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 9 months ago

Rani Therapeutics Holdings Quarterly report: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 9 months ago

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

Oct 23, 2025, 4:05 PM EDT - 10 months ago

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

Oct 23, 2025, 4:01 PM EDT - 10 months ago

Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 20, 2025, 9:42 AM EDT - 10 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CELC CRMD RAPT

Oct 17, 2025, 7:48 AM EDT - 10 months ago

Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma

Oct 17, 2025, 7:31 AM EDT - 10 months ago

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 17, 2025, 7:30 AM EDT - 10 months ago

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Registration statement: Registration Filing

Aug 7, 2025, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Rani Therapeutics Holdings Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Rani Therapeutics Holdings Quarterly report: Q2 2025

Jul 15, 2025, 9:00 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

Jul 14, 2025, 5:00 AM EDT - 1 year ago

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

Jul 3, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Registration statement: Registration Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Announces Research Agreement with Chugai

May 13, 2025, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

May 13, 2025, 9:30 AM EDT - 1 year ago

Rani Therapeutics Holdings Quarterly report: Q1 2025

May 13, 2025, 9:30 AM EDT - 1 year ago

Rani Therapeutics Holdings Earnings release: Q1 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Rani Therapeutics Holdings Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Rani Therapeutics Holdings Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Rani Therapeutics Holdings Earnings release: Q4 2024

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Mar 25, 2025, 6:00 PM EDT - 1 year ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Dec 4, 2024, 12:55 PM EST - 1 year ago

Rani Therapeutics Holdings Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 18, 2024, 4:10 PM EST - 1 year ago

Rani Therapeutics Holdings Transcript: Stifel 2024 Healthcare Conference

Nov 14, 2024, 1:15 PM EST - 1 year ago

Rani Therapeutics Holdings Transcript: UBS Global Healthcare Conference 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Rani Therapeutics Holdings Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Rani Therapeutics Holdings Earnings release: Q3 2024

Oct 15, 2024, 8:30 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

Oct 8, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 18, 2024, 11:30 AM EDT - 2 years ago

Rani Therapeutics Holdings Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 3, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Participate in September Investor Conferences

Aug 13, 2024, 3:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 6, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Aug 6, 2024, 6:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Quarterly report: Q2 2024

Aug 6, 2024, 6:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Earnings release: Q2 2024

Jul 29, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Participate in August Investor Conferences

Jul 22, 2024, 8:30 AM EDT - 2 years ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

Jun 24, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Transcript: Investor Update

Jun 24, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Press release: Investor Update

Jun 24, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Slides: Investor Update

Jun 24, 2024, 7:00 AM EDT - 2 years ago

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

May 20, 2024, 2:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 14, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Participate in May Investor Conferences

May 9, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

May 6, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

May 6, 2024, 7:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Quarterly report: Q1 2024

May 6, 2024, 7:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Earnings release: Q1 2024

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Mar 20, 2024, 4:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Earnings Call Transcript: Q4 2023

Mar 20, 2024, 4:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Annual report: Q4 2023

Mar 20, 2024, 4:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Earnings release: Q4 2023

Mar 20, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Mar 15, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Dec 14, 2023, 8:00 AM EST - 2 years ago

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Nov 8, 2023, 4:05 PM EST - 2 years ago

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

Nov 8, 2023, 4:00 PM EST - 2 years ago

Rani Therapeutics Holdings Quarterly report: Q3 2023

Oct 19, 2023, 4:05 PM EDT - 3 years ago

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Oct 12, 2023, 4:05 PM EDT - 3 years ago

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

Sep 18, 2023, 8:00 AM EDT - 3 years ago

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

Sep 7, 2023, 4:05 PM EDT - 3 years ago

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

Aug 11, 2023, 4:05 PM EDT - 3 years ago

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

Mandalo Aug. 4 at 3:19 PM

2 · Reply

kubota2323 Aug. 4 at 2:43 PM

$RANI adding more.

1 · Reply

Hakapeszi Aug. 4 at 12:14 PM

$RANI New experienced board member https://ir.ranitherapeutics.com/news-releases/news-release-details/rani-therapeutics-appoints-michelle-gilson-board-directors

2 · Reply

BinaryLogic Aug. 2 at 11:44 PM

1 · Reply

wavw Jul. 31 at 1:53 PM

$RANI volume is decreasing day by day. MM may force retailers to sell by keeping price lower. In case if no one sells then MM may find hard to cover short positions.

1 · Reply

Jack696 Jul. 30 at 6:01 PM

$RANI everything green except this

2 · Reply

Mandalo Jul. 30 at 6:37 AM

0 · Reply

Hakapeszi Jul. 30 at 6:20 AM

2 · Reply

Mandalo Jul. 30 at 5:48 AM

3 · Reply

Mandalo Jul. 30 at 5:18 AM

2 · Reply

samuraicoder Jul. 30 at 12:49 AM

$RANI let's make something happen

0 · Reply

GWaldorf5040 Jul. 29 at 8:31 PM

$RANI Are you guys flipping o! this?

1 · Reply

am2 Jul. 29 at 6:01 PM

$RANI Starting to make a move, as I write. Maybe, finally, we are on track to reverse course in a big way.

0 · Reply

Mandalo Jul. 29 at 10:45 AM

$RANI TRANSITIONING TO COMMERCIAL The Imran family excelled at pioneering technology and securing early capital, but scaling required specialized Big Pharma and commercial execution skills. Mir Imran's strength lies in inventing, while Talat Imran excels at early-stage venture building. However, transitioning from clinical development to commercial manufacturing and major pharma partnerships demands a different skillset. To bridge this gap, Rani Therapeutics brought in seasoned industry executives: Jesper Høiland (Head of Strategy): Former Novo Nordisk executive who brings top-tier pharma negotiation power and market access strategy. Nicholas Maestas (CFO): Manages capital structure and financial growth for commercial readiness. Dr. Alireza Javadi (CTO): Drives automated manufacturing and process scalability for the RaniPill. Dr. Sara Kenkare-Mitra: Advises on complex FDA regulatory pathways and Phase III clinical execution. 😇🤑👍

0 · Reply

AceInRisk Jul. 28 at 2:05 PM

$RANI Folks do you think if this will be above a $1.00 before the Nasdaq deadline compliance? I thought the results were good enough take us back to a $1 or 2. Not sure what’s happening any news from the management about addressing this? I don’t want another…. Any catalyst we are looking

3 · Reply

wavw Jul. 27 at 3:13 PM

$RANI I was wrong. The bio market moves based on FED rate decision

0 · Reply

wavw Jul. 27 at 1:35 PM

$RANI this’ll move up

0 · Reply

APRadek Jul. 25 at 12:51 PM

$RANI rNPV is 12-15$ per share(with this dillution) in bull case scenario for rt-114 program according to chatgpt.

3 · Reply

Hakapeszi Jul. 25 at 10:03 AM

$RANI promising week behind. I trust trading will continue above 0.8 with solid volume. Positive news dropped in the Q2 call shall push it above 1. Following, positive data of additional phase 1a cohort will stabilize the price well above 1.

0 · Reply

nerowinger Jul. 24 at 7:51 PM

$RANI whole market crash… fridaymood

0 · Reply

Muscle24 Jul. 24 at 6:29 PM

$RANI $OTLK Team OTLK here’s my next biotech target! Oral GLP-1 candidate! I will go big on this after cashing out on OTLK’s FDA approval!! It’s been a beautiful ride ladies and gents!!!

0 · Reply

Jack696 Jul. 24 at 5:15 PM

$RANI oh well, at least we had our moment

0 · Reply

Market Cap	95.90M
Revenue (ttm)	1.63M
Net Income (ttm)	-29.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,820.25%
Debt to Equity Ratio	0.00

Volume	618,100
Avg Vol	917,672
Day's Range	N/A - N/A
Shares Out	123.88M
Stochastic %K	45%
Beta	0.78
Analysts	Strong Sell
Price Target	$7.40